{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:06Z","timestamp":1790740566786,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA\/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of patients with LA\/mUC treated with EVP at MD Anderson Cancer Center. Pneumonitis was adjudicated by pulmonology and graded using CTCAE v5.0. Prior immune checkpoint inhibitor (ICI) exposure was defined as ICI treatment before EVP initiation. Risk factors were assessed using Cox proportional hazards and Fine-Gray competing-risk regression; associations with overall survival (OS) and progression-free survival (PFS) were evaluated using extended Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pneumonitis occurred in 22 patients (7.0%), with median onset at 77\u2009days; 10 events (45%) were grade \u22653, including 1 fatal case. Prior ICI exposure was the strongest independent predictor of pneumonitis (any-grade adjusted HR 2.68; 95% CI, 1.03-6.98; P\u2009=\u2009.04; grade \u22652 adjusted HR 5.91; 95% CI, 1.94-18.02; P\u2009=\u2009.002). No other baseline variable was significantly associated with pneumonitis. Grade \u22652 pneumonitis was associated with increased mortality (HR 2.35; 95% CI, 1.02-5.45; P\u2009=\u2009.04), whereas any-grade pneumonitis was not. Twelve patients underwent treatment re-exposure; all had no clinically meaningful recurrent or worsening pneumonitis during subsequent evaluable follow-up, with 8 resuming EV plus pembrolizumab and 4 EV alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pneumonitis occurred in 7.0% of EVP-treated patients and generally arose early. Prior ICI exposure predicted pneumonitis, particularly grade \u22652 events, which were associated with increased mortality; any-grade pneumonitis and PFS were not.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag367","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:20:57Z","timestamp":1789672857000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study"],"prefix":"10.1093","volume":"31","author":[{"given":"Luis Angel","family":"Diaz Tejada","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Alexandra Pr\u00edncipe","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Alexander","family":"Flores Hernandez","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Jacques","family":"Villarreal","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy Y","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S","family":"Shroff","sequence":"additional","affiliation":[{"name":"Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":false,"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-4472","authenticated-orcid":false,"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-9717","authenticated-orcid":false,"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026092923064315800_oyag367-B1","volume-title":"Cancer Stat Facts: Bladder Cancer","author":"SEER","year":"2023"},{"key":"2026092923064315800_oyag367-B2","doi-asserted-by":"publisher","first-page":"1254906","DOI":"10.3389\/fonc.2023.1254906","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?","volume":"13","author":"Maiorano","year":"2023","journal-title":"Front Oncol."},{"key":"2026092923064315800_oyag367-B3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/1060028020960402","article-title":"Enfortumab vedotin-ejfv: a first-in-class anti-nectin-4 antibody-drug conjugate for the management of urothelial carcinoma","volume":"55","author":"Halford","year":"2021","journal-title":"Ann Pharmacother."},{"key":"2026092923064315800_oyag367-B4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"2026092923064315800_oyag367-B5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med."},{"key":"2026092923064315800_oyag367-B6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026092923064315800_oyag367-B7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med."},{"key":"2026092923064315800_oyag367-B8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med."},{"key":"2026092923064315800_oyag367-B9","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.Ccr-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026092923064315800_oyag367-B10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol."},{"key":"2026092923064315800_oyag367-B11","doi-asserted-by":"publisher","first-page":"1326715","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin\u2009+\u2009pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol."},{"key":"2026092923064315800_oyag367-B12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21037\/jtd-22-93","article-title":"Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management","volume":"14","author":"Kim","year":"2022","journal-title":"J Thorac Dis."},{"key":"2026092923064315800_oyag367-B13","doi-asserted-by":"publisher","first-page":"1607170","DOI":"10.3389\/fimmu.2025.1607170","article-title":"Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol."},{"key":"2026092923064315800_oyag367-B14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the fleischner society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026092923064315800_oyag367-B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4143\/crt.2020.543","article-title":"Sequential treatment with an immune checkpoint inhibitor followed by a small-molecule targeted agent increases drug-induced pneumonitis","volume":"53","author":"Jung","year":"2021","journal-title":"Cancer Res Treat."},{"key":"2026092923064315800_oyag367-B16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.resinv.2025.07.023","article-title":"Immune checkpoint inhibitor-related pneumonitis: from guidelines to the front lines","volume":"63","author":"Karayama","year":"2025","journal-title":"Respir Investig."},{"key":"2026092923064315800_oyag367-B17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest."},{"key":"2026092923064315800_oyag367-B18","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.1038\/s41467-025-66509-x","article-title":"Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun."},{"key":"2026092923064315800_oyag367-B19","doi-asserted-by":"publisher","first-page":"e63615","DOI":"10.7759\/cureus.63615","article-title":"Pneumonitis incidence in patients with metastatic non-small cell lung cancer on immunotherapy: a systematic review and meta-analysis","volume":"16","author":"Saowapa","year":"2024","journal-title":"Cureus."},{"key":"2026092923064315800_oyag367-B20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"2026092923064315800_oyag367-B21","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thorac Cancer."},{"key":"2026092923064315800_oyag367-B22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","article-title":"Impact of baseline interstitial lung abnormalities on pneumonitis risk in patients receiving immune checkpoint inhibitors for non-small-cell lung cancer","volume":"24","author":"Petranovic","year":"2023","journal-title":"Clin Lung Cancer."},{"key":"2026092923064315800_oyag367-B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00262-024-03792-5","article-title":"Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities","volume":"73","author":"Kikuchi","year":"2024","journal-title":"Cancer Immunol Immunother."},{"key":"2026092923064315800_oyag367-B24","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/oncolo\/oyad187","article-title":"Pre-existing interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis in solid tumors: a retrospective analysis","volume":"29","author":"Horiuchi","year":"2024","journal-title":"Oncologist."},{"key":"2026092923064315800_oyag367-B25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejca.2022.07.014","article-title":"Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure","volume":"174","author":"Yoon","year":"2022","journal-title":"Eur J Cancer."},{"key":"2026092923064315800_oyag367-B26","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.Can-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"2026092923064315800_oyag367-B27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"2026092923064315800_oyag367-B28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"2026092923064315800_oyag367-B29","doi-asserted-by":"publisher","first-page":"730320","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol."},{"key":"2026092923064315800_oyag367-B30","doi-asserted-by":"publisher","first-page":"1527690","DOI":"10.3389\/fonc.2025.1527690","article-title":"Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag367\/71200452\/oyag367.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag367\/71200452\/oyag367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag367\/71200452\/oyag367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:06:55Z","timestamp":1790737615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag367\/8813939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag367","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag367"}}